About Palomar Labs
Palomar Labs builds and funds drug companies for people with conditions tied to the aging brain. It selects treatment programs, develops new intellectual property, and creates a separate business around each one. One of those companies, Ariadne Bio, is developing AB-300 for apathy in Parkinson's disease and related brain-aging conditions.
Palomar is headquartered in New York and operates in Vienna and Tel Aviv. Shlomi Raz is its managing partner. Ariadne Bio is also based in New York, with clinical operations in Israel and Austria.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 22, 2026 | Aug 27, 2026amended Nov 13, 2026 | $4,400,000fully sold | 13 | $338K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Dec 2, 2024 | Mar 18, 2025amended Aug 27, 2026 | $7,105,908fully sold | 18 | $394K | Fund interestsRule 506(b) | Form D/A ↗1 earlier filing |
| Total, two offerings | $11,505,908 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Palomar Labs's Form D filed Nov 13, 2026.

- Eleusis Holdings, director: Mar 4, 2022
- Palomar Labs, managing partner and director: Mar 18, 2025 · Aug 27, 2026 (2 filings) · Nov 13, 2026 (amended)
Why Investors Backed Palomar Labs
Apathy affects about 40% of people with Parkinson's during the illness, and no therapy is approved specifically for it. Caregiver-burden studies rank neuropsychiatric symptoms, including apathy, ahead of motor symptoms as drivers of distress. Palomar starts with compounds that have documented human exposure, then develops non-hallucinogenic forms for diseases without approved treatment. [3]
Origin and Team
Palomar previously operated as Negev Labs. Ariadne Bio is Shlomi Raz's second neuropsychiatry company. Raz founded Eleusis to develop medicines derived from psychedelic compounds. Beckley Psytech acquired Eleusis in 2022. Raz later served as Beckley Psytech's president and previously was a Goldman Sachs managing director. Beckley Psytech combined with Atai Life Sciences in 2025 to form AtaiBeckley. Eli Lilly announced an agreement to acquire AtaiBeckley on July 16, 2026. Raz now leads Ariadne as founder and chief executive officer. [1][3]
Product and Technology
Ariadne's lead medicine activates a serotonin target called the 2A receptor without causing hallucinations. The candidate, AB-300, is ready for clinical development in Parkinson's-related apathy and similar brain-aging conditions. [3]
A preclinical test used tetrabenazine to cause a motivation deficit and measured effort-based behavior. Adding AB-300 increased motivated behavior by 89% versus tetrabenazine alone, a statistically significant result. The effect was strongest in the group with the greatest starting deficit. [3]
Screening found no measurable activity at dopamine receptors or the system that transports dopamine. This supports a mechanism independent of direct dopamine signaling. [3]
An early clinical trial, called Phase 1b, was expected to begin in the second half of 2026 at sites in Israel and Austria. AB-300 remains experimental. Its safety and efficacy have not been established, and no regulator has approved it. [3]
Use of Funds
- The Michael J. Fox Foundation's Parkinson's Disease Therapeutics Pipeline Program will fund Ariadne Bio's Phase 1b trial of AB-300. [3]
Milestones
Scroll table to see all columns →
| Date | What happened | Source | Coverage |
|---|---|---|---|
| Sep 17, 2026 | Palomar spun out Ariadne Bio as its first portfolio company. | [3] | Drug Discovery World ↗Genetic Engineering & Biotechnology News ↗BioWorld ↗ |
| May 2026 | Ariadne presented AB-300 preclinical data at the American Society of Clinical Psychopharmacology annual meeting. | [3] | — |
| 2026 | Ariadne completed a formal drug-development meeting, called a Type B pre-IND meeting, with the FDA. | [3] | — |
Market
Daniel E. Jeffries, Ariadne's chief development officer, sees serotonin pathways as the more relevant signal for apathy in untreated Parkinson's. He cites human brain imaging that linked apathy severity to serotonin markers rather than dopamine markers. [3]
We wrote this summary from public statements by Palomar Labs and its investors. It is not investment advice.
Sources
- CompanyPalomar Labs official website · linked above ↑
- CompanyPalomar Labs privacy policy
- CompanyAriadne Bio release on the Palomar Labs spinout
- SECPalomar Labs Form D/A, filed 2026-11-13 · linked above ↑
- SECPalomar Labs Form D, filed 2026-08-27
- SECPalomar Labs Form D, filed 2025-03-18
- SECPalomar Labs Form D/A, filed 2026-08-27 · linked above ↑
- SECPalomar Labs Holdings LLC filing history